Medetomidine in the Illicit Drug Supply: What Pharmacists Need to Know About "Rhino Tranq" and Naloxone-Resistant Overdoses

The opioid crisis in the United States continues to evolve into a complex polysubstance epidemic, with increasingly unpredictable drug formulations contributing to rising overdose morbidity and mortality. In addition to opioids such as fentanyl, the growing presence of nonopioid adulterants has complicated overdose recognition and response, as these agents produce effects that are not reversed by readily available opioid antagonists such as naloxone.

Xylazine “tranq” was previously identified as a widespread fentanyl adulterant, but emerging data now point to a shift toward medetomidine, commonly called “rhino tranq,” a more potent α2 adrenergic agonist that has rapidly entered the illicit drug supply and is associated with more severe and prolonged toxicity.¹ This transition presents significant clinical challenges, as patients may exhibit persistent sedation and cardiovascular instability despite naloxone administration, requiring advanced supportive care. Consequently, pharmacists and frontline clinicians play a critical role in recognizing these evolving overdose patterns, adapting response strategies, and supporting harm reduction efforts in an increasingly complex drug landscape.

Pharmacology of Medetomidine

Medetomidine is a veterinary sedative classified as a highly potent and selective α2-adrenergic receptor agonist. It exerts its effects primarily through inhibition of norepinephrine release in the central nervous system, particularly within the locus coeruleus, resulting in dose-dependent central nervous system (CNS) depression.^2,3 This decrease in sympathetic outflow produces pronounced sedation and analgesia, along with sympatholytic effects such as bradycardia and hypotension.^1,4 These effects are mediated through both presynaptic inhibition of norepinephrine release and postsynaptic α2-adrenergic receptor activation, which together suppress central arousal pathways and modulate pain signaling.^3,4

Compared with xylazine, another α2-adrenergic agonist previously identified in the illicit drug supply, medetomidine demonstrates greater receptor selectivity and potency. These pharmacologic characteristics may increase its potential utility as an adulterant and filler in illicit fentanyl formulations, as enhanced α2-agonist activity can prolong and intensify sedation. Importantly, because its mechanism of action does not involve opioid receptors, standard reversal with naloxone does not mitigate its CNS depressant effects, increasing the risk of prolonged sedation and complex overdose presentations.⁵

Clinical Effects and Toxicity

Medetomidine-adulterated fentanyl exposure produces a distinct toxidrome characterized by profound sedation, respiratory depression, bradycardia, and hypotension, reflecting the combined depressant effects of opioids and potent α2 adrenergic agonism. Clinical data demonstrate that intoxicated patients frequently present with deep, prolonged sedation accompanied by marked bradycardia and low blood pressure, often requiring hospital admission and, in severe cases, intensive care support.⁶

Although naloxone remains critical for reversing the opioid component of a fentanyl or other opioid overdose, it does not counteract medetomidine’s nonopioid effects, resulting in persistent sedation and incomplete neurologic recovery. This leads to delayed clinical improvement, increasing the risk of recurrent respiratory depression if opioid effects persist longer than the naloxone-induced reversal. As a result, these overdoses present significant challenges in emergency management, requiring extended monitoring, airway support when necessary, and heightened clinical suspicion for nonopioid adulterants in patients who do not fully respond to naloxone.⁶

Withdrawal Syndrome and Hospital Complication

Clinical observations suggest that repetitive exposure to medetomidine causes a distinct withdrawal syndrome arising from dysregulation of the sympathetic nervous system. After the acute effects of medetomidine wear off, rebound symptoms present in the form of hypertension, tachycardia, agitation, tremors, and vomiting, pointing toward excessive norepinephrine release.⁴ With new reports of fentanyl containing medetomidine, patient symptoms are noticeably different from simple opioid withdrawal in both severity and clinical instability, often leading to the need for intensive care unit monitoring due to adverse cardiovascular effects and the risk of rapid deterioration.⁷

Clinically, this presentation is consistent with an acute hyperadrenergic state, similar to withdrawal from other alpha-2 adrenergic agonists, such as dexmedetomidine, thus complicating diagnosis and treatment.⁴ As medetomidine becomes more common in the illicit drug supply, patients are requiring longer stays and higher levels of care. Additionally, the absence of standardized management protocols continues to challenge clinicians and emphasizes the need for improved surveillance and treatment strategies.^8,9 In response to this growing concern, states like New York have issued updated health alerts and are implementing harm reduction strategies, including the purchase of medetomidine drug-checking test strips to support community drug-checking program partners, ensuring timely access to reliable tools for detecting medetomidine in the drug supply.⁹

Treatment Challenges and Current Management

There are currently no FDA-approved therapies for xylazine and medetomidine toxicity in humans, leading to significant challenges in managing drug-related clinical cases. Agents such as atipamezole, which has been used in veterinary medicine to reverse the effects of medetomidine and other α2-adrenergic agonists used as anesthetic agents, are not approved for human use.¹⁰ Instead, current management strategies focus on symptomatic treatment, supporting patients with medications such as clonidine or dexmedetomidine to manage withdrawal-related symptoms, and slowly tapering down the extent of the α2-adrenergic agonism while monitoring respiratory and cardiovascular activity, as well as continuing toxicology screenings.⁵

Implications for Pharmacists and Public Health

Pharmacists and public health officials both play an important role in responding to overdose risk by providing overdose response education and improved screening measures. Many overdoses today contain multiple substances, such as the adulteration of fentanyl with xylazine or medetomidine as a filler. Naloxone only reverses opioid overdoses; however, it should still be administered in the event of an overdose because the effects of the medication are still potentially fatal. In opioid-related cases, naloxone will provide immediate improvement in cognition and respiratory function.² However, if naloxone administration does not reverse persistent sedation, this likely predicts the presence of non-opioid adulterants, such as α2-adrenergic agonists.

Pharmacists should educate patients on the limited effects of naloxone in the presence of opioid plus non-opioid-related overdoses and support them by providing community resources and counseling, when needed. Public health officials should focus their efforts on preventive measures, including improving drug surveillance systems by expanding toxicology testing capabilities and drug-checking programs. These initiatives would allow for improved data on the prevalence and incidence of drug-related cases involving non-opioid adulterants, enabling more research on screening systems to help enhance education on recognizing and managing increasingly complex overdoses.²

Conclusion

Medetomidine represents a dangerous evolution in the adulterant phase of the opioid crisis, introducing a more potent and longer-acting class of non-opioid sedatives into the illicit drug supply. Current overdose response models, which primarily rely on opioid antagonists such as naloxone, may be insufficient to address the prolonged and complex effects associated with α2-adrenergic agonists. This highlights the urgent need for expanded research and development of clinical management guidelines with improved surveillance systems to detect emerging substances. Hence, pharmacists play a critical role in this response by recognizing atypical overdose presentations, educating patients and communities, and supporting harm reduction and public health monitoring efforts.

REFERENCES

1. Zhu DT, Palamar JJ. Responding to medetomidine: clinical and public health needs. Lancet. 2025;44:101053. doi:10.1016/j.lana.2025.101053

2. Fan S, Cheng X, Zhang P, Wang Y, Wang L, Cheng J. The α2 adrenoceptor agonist and sedative/anaesthetic dexmedetomidine excites diverse neuronal types in the ventrolateral preoptic area of male mice. ASN Neuro. 2023;15(1). doi:10.1177/17590914231191016

3. Horn PA, Berida TI, Parr LC, et al. Classics in chemical neuroscience: medetomidine. ACS Chem Neurosci. 2024;15(21):3874-3883. doi:10.1021/acschemneuro.4c00583

4. McKenzie CA, Walsh TS. Pharmacology of alpha-2 agonists applied to sedation, sleep, and analgesia. Crit Care Clinics. 2025;41(4):641-663. doi:10.1016/j.ccc.2025.05.007

5. Owusu-Antwi P, Atodaria P, Appiah-Kubi E, Shah Z, Garcia EM. Management of xylazine toxicity, overdose, dependence, and withdrawal: a systematic review. Am J Addict. 2025;34(6):589-602. doi:10.1111/ajad.70051

6. Durney P, Kahoud JL, Warrick-Stone T, et al. Biochemical identification and clinical description of medetomidine exposure in people who use fentanyl in Philadelphia, PA. Int J Molec Sci. 2025;26(14):6715. doi:10.3390/ijms26146715

7. Huo S, London K, Murphy L, et al. Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients—Philadephia, Pennsylvania, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):266-268. doi:10.15585/mmwr.mm7415a2

8. Health officials finding different illicit veterinary sedative in US drug supply. American Veterinary Medical Association. June 23, 2025. Accessed May 13, 2026. https://www.avma.org/news/health-officials-finding-different-illicit-veterinary-sedative-us-drug-supply

9. New York State Department of Health warns of highly potent synthetic sedative more powerful than xylazine emerging in drug checking samples. News release. New York State Department of Health. December 19, 2025. Accessed May 13, 2026. https://www.health.ny.gov/press/releases/2025/2025-12-19_synthetic_sedative.htm

10. Britsch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances. Psychopharmacology (Berl). 2022;239(7):2063-2081. doi:10.1007/s00213-022-06125-5

11. Shaw LV, Moe J, Purssell R, et al. Naloxone interventions in opioid overdoses: a systematic review protocol. Syst Rev. 2019;8(1):138. doi:10.1186/s13643-019-1048-y